Rafael Holdings, Inc. (RFL) Company Overview

What does Rafael Holdings do today?

Rafael Holdings, Inc. is a New York Stock Exchange-listed biotechnology holding company whose Class B shares trade under the ticker RFL. Its current identity is very different from a conventional revenue-generating pharmaceutical manufacturer. Rafael develops and finances clinical-stage therapeutics and medical-device businesses, with its most important asset now being Trappsol Cyclo, a hydroxypropyl beta cyclodextrin candidate being studied for Niemann-Pick Disease Type C1, or NPC1. The company’s fiscal 2025 Form 10-K describes Rafael as a biotechnology company that develops pharmaceuticals and holds interests in clinical and early-stage pharmaceutical and medical-device companies.

Which businesses sit inside the portfolio?

This mix means Rafael should be analyzed primarily as a clinical-development and capital-allocation vehicle, not as a mature operating company. Its reported revenue is too small to explain enterprise value by itself. The central analytical question is whether the clinical portfolio can create future licensing, partnership or product economics before cash resources are depleted.

How does Rafael Holdings make money?

Rafael currently has three small revenue streams: specialty-chemical product sales associated with Cyclo, rent from third-party tenants, and rent from related parties. In the nine months ended April 30, 2026, total revenue was $630,000, consisting of $368,000 of product revenue, $173,000 of third-party rent and $89,000 of related-party rent. Infusion Technology contributed no revenue in that period. The latest Form 10-Q for the quarter ended April 30, 2026 makes clear that these activities do not cover corporate and clinical-development costs.

Why is current revenue not the main valuation driver?

Clinical-stage biotechnology companies often incur years of research expense before a product can generate commercial sales. Rafael’s economic model therefore depends on future events: successful trial outcomes, regulatory progress, licensing transactions, partnerships, asset sales or eventual commercialization. Trappsol Cyclo is the most advanced program, and the company announced in a June 2026 Form 8-K that the final patient had completed the 96-week visit in the pivotal Phase 3 TransportNPC study and that topline data from the main cohort were expected in the second half of 2026.

What does the latest reported period show?

The quarter ended April 30, 2026 showed a company with minimal operating revenue, rising clinical spending and a still meaningful but shrinking cash balance. Quarterly revenue fell to $179,000 from $362,000 a year earlier. Research and development expense rose to $4.9 million from $3.0 million, while general and administrative expense declined to $2.1 million from $3.2 million. The operating loss widened to $6.9 million from $5.9 million.

What changed over the first nine months?

For the nine months ended April 30, 2026, revenue increased modestly to $630,000 from $567,000, but R&D expense surged to $16.9 million from $5.3 million after the March 2025 Cyclo acquisition. The nine-month operating loss was $23.7 million, compared with $16.4 million. Net loss attributable to Rafael was $20.5 million, or $0.40 per diluted share, compared with $18.4 million, or $0.73 per share. The smaller per-share loss despite a larger absolute loss reflects the substantial increase in weighted-average shares after the Cyclo transaction and 2025 rights offering.

How did Rafael’s strategy evolve?

Rafael’s current profile emerged through a sequence of portfolio shifts rather than a single operating build-out. Understanding those shifts is essential because they explain both the company’s unusual assets and the risks embedded in its governance and capital allocation.

1. 2018
   IDT completed the spin-off of Rafael. The transaction created a separately listed vehicle with real estate and life-sciences interests, while retaining important related-party connections.
2. 2019
   Rafael established Barer Institute to pursue cancer-metabolism research and external collaborations, increasing exposure to early-stage scientific risk.
3. 2022
   The company curtailed most Barer research activity, signaling greater selectivity after early-stage programs failed to justify continued internal spending.
4. 2023
   Rafael first invested in Cyclo Therapeutics, gaining exposure to Trappsol Cyclo and rare-disease development.
5. 2024
   Cornerstone completed a restructuring that made Rafael a 67% owner and consolidated the business into Rafael’s financial statements.
6. 2025
   Rafael completed the Cyclo merger on March 25, making Cyclo wholly owned. A $25 million rights offering then expanded the share count and replenished capital.
7. 2026
   The final patient completed the pivotal TransportNPC study visit, making the second-half 2026 topline readout the company’s most important near-term milestone.

What did the Cyclo merger change?

Before the merger, Rafael held a portfolio of investments and majority stakes. After the merger, it directly controlled the asset with the clearest late-stage clinical path. That concentrated scientific and financial attention on Trappsol Cyclo, but it also increased consolidated R&D expense and reduced diversification. The March 2025 merger filing is therefore the pivotal transaction for understanding the current company.

Why is Trappsol Cyclo the decisive asset?

NPC1 is a rare, fatal genetic disorder involving disrupted intracellular cholesterol transport and progressive neurological and systemic damage. Trappsol Cyclo is intended to address the disease through systemic administration of hydroxypropyl beta cyclodextrin. The program received FDA Fast Track designation in January 2017, and the pivotal Phase 3 TransportNPC study includes pediatric and adult patients. Rafael’s July 2026 investor-presentation filing highlights the program’s strategic priority.

What would positive data unlock?

Positive results could support discussions with regulators, further study planning, financing alternatives and potential commercial or licensing partners. For a small biotechnology company, a credible regulatory path can materially change the cost of capital and bargaining position. It would not guarantee approval, reimbursement or commercial success, but it could convert Rafael from a broad portfolio company into a company anchored by a defined late-stage rare-disease program.

What could weaken the program’s value?

Weak efficacy, safety concerns, ambiguous endpoint interpretation, additional trial requirements, manufacturing complexity or limited payer economics could reduce the asset’s value. Rare-disease trials also face small populations, heterogeneous disease progression and statistical sensitivity. Rafael’s annual report identifies clinical, regulatory, financing and intellectual-property risks typical of development-stage biotechnology, but those risks are especially concentrated because Trappsol Cyclo is the leading program.

How strong is Rafael Holdings’ financial position?

At April 30, 2026, Rafael reported $30.5 million of cash and cash equivalents, down from $52.8 million at July 31, 2025. Working capital fell to $23.8 million from $45.1 million, total assets declined to $92.0 million from $114.1 million, and total equity declined to $80.8 million from $98.4 million. Management stated that available cash was expected to fund obligations for at least twelve months from the Form 10-Q filing date, but that statement should not be confused with a long-duration commercial runway.

What is the cash-burn signal?

Operating cash use of $21.6 million over nine months equaled roughly 71% of the April 30 cash balance. A simple annualized extrapolation would be inappropriate because trial timing, milestone payments and corporate actions can vary, but the ratio shows why clinical data and financing strategy matter. Rafael’s operating model presently converts capital into research activity rather than free cash flow. A DCF based on near-term operating cash generation would therefore be misleading; probability-adjusted asset valuation and runway analysis are more relevant.

Who owns Rafael stock, and why does control matter?

Rafael has a dual-class voting structure that separates economic ownership from voting power. As of the November 2025 proxy record date, 787,163 Class A shares and 50,975,638 Class B shares were outstanding. Each Class A share carried three votes, while each Class B share carried one-tenth of one vote. The 2025 proxy statement reported that Howard S. Jonas beneficially owned all Class A shares, 14.0 million Class B shares and 50.4% of aggregate voting power.

How did the rights offering reinforce control?

In the fiscal 2025 rights offering, Rafael sold approximately $25 million of Class B shares at $1.28 per share. Howard Jonas and related parties purchased roughly 16.4 million unsubscribed shares for about $21 million under a standby agreement. The transaction strengthened liquidity but also increased family-related ownership and underscored the company’s reliance on its controlling shareholder for capital support.

What governance tension should researchers note?

The structure can support decisive, long-term action when public markets are unwilling to finance clinical risk. It can also reduce the influence of minority shareholders and heighten the importance of related-party oversight. The proxy disclosed continuing transactions with IDT, a company also connected to Howard Jonas, including administrative services and Jerusalem office rent. Rafael’s governance analysis therefore requires attention to board independence, related-party review and whether capital allocation benefits all shareholders proportionately.

What gives Rafael a competitive advantage?

Rafael does not possess a conventional moat based on scale, recurring revenue or commercial distribution. Its potential advantages are narrower: control of a late-stage rare-disease asset, concentrated decision-making, access to a supportive shareholder base, and a portfolio that may produce licensing optionality. These are valuable only if the science and execution are credible.

Who competes with Rafael?

Competition occurs at several levels. Trappsol Cyclo competes with existing NPC treatments, investigational therapies and academic or biotechnology programs pursuing alternative mechanisms. Rafael also competes for rare-disease patients, trial sites, specialist attention, experienced personnel, manufacturing capacity and investor capital. Because NPC1 is rare, the practical competitive field is not simply measured by market share; speed of development, quality of evidence, regulatory relationships and caregiver trust matter more.

Which KPIs matter most for Rafael?

Traditional growth metrics such as same-store sales or recurring revenue are not useful here. Rafael’s most decision-relevant indicators measure clinical progress, spending intensity, liquidity and ownership structure.

How should students interpret the expense base?

For the nine months ended April 30, 2026, R&D expense of $16.9 million was approximately 26.8 times total revenue of $630,000. That ratio is not a gross-margin problem; it is evidence that the company is financing development rather than operating a commercial platform. General and administrative expense of $7.3 million was also large relative to revenue. The relevant question is whether those costs are tightly connected to value-creating milestones.

What opportunities and risks could change the story?

The opportunity set is concentrated but meaningful. Positive TransportNPC data could improve partnering leverage, financing access and strategic credibility. Rafael could also monetize secondary assets through licenses or external investment, reduce overhead further, or use its controlled structure to make fast portfolio decisions. The real-estate asset and specialty-product revenue provide only modest support, but they add small sources of cash outside clinical funding.

Which risks are most material?

• Clinical risk: the lead program may fail to meet efficacy or safety expectations, or results may be difficult to interpret.
• Regulatory risk: regulators may require additional studies, manufacturing work or longer follow-up before considering approval.
• Financing risk: continued negative cash flow may force equity issuance, asset sales or partner-dependent funding.
• Concentration risk: Trappsol Cyclo dominates the near-term narrative, while most other assets are earlier or strategically uncertain.
• Governance risk: dual-class voting and related-party relationships limit minority influence and require strong conflict oversight.
• Execution risk: a small organization must manage trials, regulatory work, manufacturing and portfolio decisions simultaneously.
• Commercial risk: even an approved rare-disease therapy must secure diagnosis, specialist adoption, reimbursement and supply reliability.

What should researchers monitor next?

Why does Rafael matter for valuation?

Rafael cannot be valued sensibly by applying a normal revenue multiple to $630,000 of nine-month revenue. Its financial statements mainly reveal the cost of maintaining the portfolio and the amount of capital available to reach milestones. A more useful analytical framework separates net cash and other tangible assets from probability-adjusted clinical value, then subtracts expected future development and corporate costs.

Which assumptions dominate a DCF or asset-based model?

The dominant assumptions are probability of technical and regulatory success, timing to approval, eligible patient population, treatment duration, net price, market penetration, manufacturing cost, partner economics, required future trials and the discount rate applied to a binary asset. Because modest changes in those inputs can produce large valuation swings, scenario analysis is more informative than a single-point forecast.

Researchers should also adjust for governance and financing. The dual-class structure can lower the probability of an unwanted strategic shift, but it can also reduce minority influence. Future capital may come from the controlling shareholder, public equity, strategic partners or asset monetization, and each route has different dilution and control consequences.

What is the key takeaway from Rafael Holdings analysis?

Rafael Holdings is best understood as a controlled, development-stage biotechnology portfolio whose near-term value is concentrated in Trappsol Cyclo. The company has enough reported liquidity to continue operating in the near term, but its $30.5 million cash balance at April 30, 2026 must be judged against $21.6 million of operating cash use over the preceding nine months. Current product and rental revenue are real but immaterial relative to clinical spending.

For students and researchers, Rafael is a useful case study in how biotechnology valuation differs from conventional corporate analysis. Revenue history and accounting profit matter less than clinical probability, cash runway, ownership control and capital allocation. For investors, the company’s story is neither a simple growth thesis nor a diversified pharmaceutical model. It is a milestone-driven situation in which one late-stage program, one concentrated shareholder structure and one finite pool of capital jointly determine the range of outcomes.